RecruitingPhase 4NCT05421767
Renal Nerve Stimulation in Uncontrolled Hypertensive Patients Undergoing Renal Denervation
National Tawan University Hospital
Sponsor
National Taiwan University Hospital
Enrollment
60 participants
Start Date
Jun 24, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
Study design: Investigator initiated, single center The study is aimed 1\) To investigate the blood pressure (BP) change to renal nerve stimulation(RNS), and subsequently perform a renal denervation(RDN) procedure 1\) to verify the cutoff value (RNS-induced systolic BP change \<20 mmHg in post-RDN patients) could be a useful clinical endpoint in RDN therapy, and test the hypothesis that intense RDN could improve the efficacy of RDN.
Eligibility
Min Age: 20 Years
Inclusion Criteria4
- Patients with hypertension (HTN), including
- hour ambulatory blood pressure \>130/ 80 mmHg
- Age 20-80 years
- Glomerular filtration rate \>45 mL/min
Exclusion Criteria2
- Unsuitable renal artery anatomy computed tomographic angiography (main renal artery lumen diameter ≤3 mm or a total length \<20 mm of the main arteries).
- untreated secondary HTN, including hyperaldosteronism, pheochromocytoma, renal artery stenosis(\>50% stenosis)
Interventions
PROCEDUREnerve stimulation guided renal denervation procedure
RNS-in
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05421767
Related Trials
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT070644731153 locations
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT0605963898 locations
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
NCT052937561 location
Coaching and Navigation by Community Health Workers (CHWs) Through Telehealth for High-risk Hypertension
NCT074614154 locations
SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism
NCT074820201 location